Literature DB >> 25237942

Evaluation of 1p and 14q status, MIB-1 labeling index and progesterone receptor immunoexpression in meningiomas: Adjuncts to histopathological grading and predictors of aggressive behavior.

Sawan Kumar, Aanchal Kakkar, Vaishali Suri1, Anupam Kumar, Utkarsh Bhagat, Mehar Chand Sharma, Manmohan Singh, Ashish Suri, Chitra Sarkar.   

Abstract

BACKGROUND: Meningiomas are benign central nervous system tumors; however, significant fraction recurs, irrespective of histological grade.
MATERIALS AND METHODS: We performed fluorescence in-situ hybridization for 1p36 and 14q32, and immunohistochemistry for progesterone receptor (PR), p53 and MIB-1 on 84 meningiomas. RESULTS AND
CONCLUSION: Sixty-four were convexity tumors (30 grade I, 21 grade II, 13 grade III) and 20 petroclival (grade I; 10 with gross total resection (GTR), 10 with subtotal resection (STR)). Isolated 1p36 deletion was seen in 20% grade I, 28.6% grade II and 30.8% grade III convexity meningiomas, and isolated 14q deletion in one grade III convexity tumor. 1p/14q co-deletion was seen in none of grade I, 28.5% grade II and 30% grade III convexity meningiomas. PR immunoreactivity was less frequent in grade III tumors. Petroclival tumors did not show isolated deletion. However, 1p/14q co-deletion was seen in 20% of petroclival tumors with STR and in none with GTR. Frequency of chromosomal alterations and MIB-1 labeling index both increase with tumor grade. 1p/14q co-deletion is characteristic of grade II/III meningiomas, while PR immunoreactivity inversely correlates with grade, suggesting their use as surrogate markers for grading. Identification of 1p/14q co-deletion in grade I petroclival tumors with STR suggests that unresectable petroclival meningiomas are biologically more aggressive than their grade I convexity counterparts.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25237942     DOI: 10.4103/0028-3886.141248

Source DB:  PubMed          Journal:  Neurol India        ISSN: 0028-3886            Impact factor:   2.117


  4 in total

1.  Expression of p40 (∆Np63) protein in meningiomas, an unexpected finding: immunohistochemical study and evaluation of its possible prognostic role.

Authors:  Elia Guadagno; Marialaura Del Basso De Caro; Sara Pignatiello; Concetta Sciammarella; Domenico Solari; Paolo Cappabianca; Francesco Maiuri; Flavia Dones
Journal:  J Neurooncol       Date:  2016-07-09       Impact factor: 4.130

2.  Multiplatform profiling of meningioma provides molecular insight and prioritization of drug targets for rational clinical trial design.

Authors:  Richard G Everson; Yuuri Hashimoto; Jacob L Freeman; Tiffany R Hodges; Jason Huse; Shouhao Zhou; Joanne Xiu; David Spetzler; Nader Sanai; Lyndon Kim; Santosh Kesari; Andrew Brenner; Franco De Monte; Amy Heimberger; Shaan M Raza
Journal:  J Neurooncol       Date:  2018-05-30       Impact factor: 4.130

3.  Histopathological and Immunohistochemical Evaluation of Meningiomas with Reference to Proliferative Markers p53 and Ki-67.

Authors:  Ramesh Babu Telugu; Amit Kumar Chowhan; Nandyala Rukmangadha; Rashmi Patnayak; Bobbidi Venkata Phaneendra; Bodapati Chandra Mowliswara Prasad; Mandyam Kumaraswamy Reddy
Journal:  J Clin Diagn Res       Date:  2016-01-01

4.  Evaluation of P57, P53 and Ki67 Expression in Meningiomas.

Authors:  İlknur Küçükosmanoğlu; Meryem İlkay Eren Karanis; Yaşar Ünlü; İlker Çöven
Journal:  J Korean Neurosurg Soc       Date:  2022-04-14
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.